# Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors

> **NCT07661797** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 294 (estimated)

## Conditions studied

- Patients With Advanced Solid Tumors

## Interventions

- **DRUG:** LNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4)

## Key facts

- **NCT ID:** NCT07661797
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-06
- **Final completion:** 2028-08
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07661797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07661797, "Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07661797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*